Gaglani, Manjusha

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021

Thompson, M. G., Burgess, J. L., Naleway, A. L., Tyner, H. L., Yoon, S. K., Meece, J., Olsho, L. E. W., Caban-Martinez, A. J., Fowlkes, A., Lutrick, K., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 707

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

Lauring, A. S., Tenforde, M. W., Chappell, J. D., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2022) · BMJ

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 656

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Tenforde, M. W., Self, W. H., Adams, K., Gaglani, M., Ginde, A. A., McNeal, T., Ghamande, S., Douin, D. J., Talbot, H. K., Casey, J. D., et al. (2021) · JAMA

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 633

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 435

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Self, W. H., Tenforde, M. W., Rhoads, J. P., Gaglani, M., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 406

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022

Thompson, M. G., Natarajan, K., Irving, S. A., Rowley, E. A., Griggs, E. P., Gaglani, M., Klein, N. P., Grannis, S. J., DeSilva, M. B., Stenehjem, E., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 398

Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults — United States, March–July 2021

Tenforde, M. W., Self, W. H., Naioti, E. A., Ginde, A. A., Douin, D. J., Olson, S. M., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2021) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 204

Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study

Ferdinands, J. M., Rao, S., Dixon, B. E., Mitchell, P. K., DeSilva, M. B., Irving, S. A., Lewis, N., Natarajan, K., Stenehjem, E., Grannis, S. J., et al. (2022) · BMJ

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 185

Effectiveness of mRNA Vaccination in Preventing COVID-19–Associated Invasive Mechanical Ventilation and Death — United States, March 2021–January 2022

Tenforde, M. W., Self, W. H., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., McNeal, T., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 170

Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022

Link-Gelles, R., Levy, M. E., Gaglani, M., Irving, S. A., Stockwell, M., Dascomb, K., DeSilva, M. B., Reese, S. E., Liao, I.-C., Ong, T. C., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 126

Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study

Adams, K., Rhoads, J. P., Surie, D., Gaglani, M., Ginde, A. A., McNeal, T., Talbot, H. K., Casey, J. D., Zepeski, A., Shapiro, N. I., et al. (2022) · BMJ

SARS-CoV-2 and COVID-19 ResearchVaccine Coverage and Hesitancy

Cited by 115

Effectiveness of Monovalent mRNA Vaccines Against COVID-19–Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States — IVY Network, 18 States, December 26, 2021–August 31, 2022

Surie, D., Bonnell, L., Adams, K., Gaglani, M., Ginde, A. A., Douin, D. J., Talbot, H. K., Casey, J. D., Mohr, N. M., Zepeski, A., et al. (2022) · MMWR. Morbidity and Mortality Weekly Report

SARS-CoV-2 and COVID-19 ResearchCOVID-19 epidemiological studies

Cited by 59

Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods

Link-Gelles, R., Levy, M. E., Natarajan, K., Reese, S. E., Naleway, A. L., Grannis, S. J., Klein, N. P., DeSilva, M. B., Ong, T. C., Gaglani, M., et al. (2022) · medRxiv

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 10